Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-908-4
CAS number: 101-02-0
TPP produced evidence of neurotoxicity in the presence of other signs of systemic toxicity at an oral dose of 40 mg/kg/day in a well conducted OECD 422 study which was extended and studied effects in F1 offspring treated to postpartum Day 70. The NOAEL for systemic toxicity (including neurotoxicity) in both the parental animals and the F1 offspring was 15 mg/kg/day.
TPPi was administered by gavage once daily at 0, 5, 15, and 40 mg/kg/day
to parental F0 CD® (SD) rats, 10/sex/group, through prebreed, mating,
gestation, and lactation and direct dosing to Fl offspring
(10/sex/group) from weaning to postpartum day 70 (Tyl, 2004). Treatment
with TPPi resulted in adult F0 parental toxicity at 40 mg/kg/day,
increasing over time (reduced body weights, ataxia, and foot splay).
F1 offspring in the 40 mg/kg/day group were terminated at pnd 22 due to
mortality and reduced body weight gain during lactation. F1 offspring
from the other groups were weaned at Day 22 and then treated with TPPi
for 7 weeks (until postpartum day 70). For these retained Fl males and
females, in-life systemic parameters (including FOB) were unaffected.
Based on these results, the F0 male and female systemic no observable
adverse effect level (NOAEL) was 15 mg/kg/day. The Fl adult male and
female systemic NOAEL was also 15 mg/kg/day.
In addition, TPP has been also been identified as a neurotoxicant, at
high doses, in a number of acute studies published in the literature,
and in a review published by Abou-Donia (1992). All of these studies
appear to have been run at concentrations one to two orders of magnitude
higher than the recent, GLP, multi-generational study conducted on TPP
(Tyl 2004), which included behavioral and neurotoxicity endpoints. As
such, the NOAEL from the Tyl study for repeat dose toxicity is also
considered to be appropriate for the neurotoxicity endpoint.
Reference: Abou-Donia MB. (1992) Triphenyl Phosphite:
A Type II Organophosphorus Compound-Induced Delayed Neurotoxic Agent. In
J. Chambers and P. Levi (Eds), Organophosphates: Chemistry, Fate and
Effects (pp 327 – 351). San Diego, CA: Academic Press.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again